Subcutaneous Herceptin Meets Goals In Phase III Trial
This article was originally published in The Pink Sheet Daily
New subcutaneous formulation of Roche's breast cancer biologic Herceptin is comparable to intravenous version, prompting the companies to file for approval in Europe in 2012. Yet, U.S. filing could take longer.
You may also be interested in...
Despite multiple partnerships around a technology platform that can ease administration of existing drugs, Halozyme says its future prospects revolve more around a significant opportunity in insulin-pump products.
Halozyme’s Enhanze technology could be used with virtually all biologics to improve drug delivery, the company says.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.